What does Credent Connect actually do?

It is a B2B healthcare-logistics and phlebotomy-manpower platform - home sample collection, stationed phlebotomists, and cold-chain transport for diagnostic labs, pharma and hospitals. It does not run labs or own any test; it is the operational backbone behind them, the picks-and-shovels of Indian diagnostics.

Why is Credent Connect's FY26 profit jump described as optical?

Because revenue was nearly flat from FY24 to FY25 (about ₹76-78 crore), then leapt to roughly ₹214 crore in FY26 largely because acquired businesses got consolidated into the accounts. The organic, like-for-like growth is far more modest than the headline suggests.

What is the bull case for Credent Connect?

Size versus opportunity: a ~₹344 crore post-listing value sitting in front of a ₹1.54 lakh crore diagnostics market growing ~12% a year. Add asset-light economics (ROCE ~40%), promoters retaining 64%, marquee smallcap backing, and scarcity as one of the few listed pure-play proxies - and it becomes a patient, long-term small-cap bet rather than a listing-day trade.

Credent Connect IPO: The Arms Dealer of Diagnostics?

Sample size: tiny. Market size: ₹1.54 lakh crore - Credent Connect ka funda.

Credent Connect IPO: the picks-and-shovels of Indian diagnostics

Credent Connect's ₹94 crore IPO closed with huge demand - about 80x subscribed, grey market premium ~25-29% - and lists on Aug 20. Here is my honest read - not investment advice.

What it does

It runs no lab and tests no one. It is the backbone behind the labs: home sample pickup, the phlebotomists who draw blood, and cold-storage transport for labs and pharma. In short, it sells the shovels while others dig for gold in diagnostics - the picks-and-shovels of the sector.

The honest bit first

Low margins (~13% EBITDA). It is a service vendor - it does not own the actual test, so it earns less than the labs it serves.
The profit jump is mostly optical. Revenue was nearly flat FY24 to FY25, then leapt to about ₹214 crore in FY26 - largely because acquired businesses got consolidated. The organic trajectory is far more modest.
Priced fairly, not cheap, at about 18.7x.

The hook

Here is why it still interests me. After listing it is worth only about ₹344 crore, standing in front of a ₹1.54 lakh crore Indian diagnostics market growing ~12% a year. A tiny player in front of a very big door. It is asset-light (ROCE ~40%), the founders keep 64% after the IPO, and it carries marquee smallcap backing (Ashish Kacholia).

The FII angle

Foreign funds already crowd into listed diagnostics - they hold roughly 17% of Dr Lal PathLabs, and by one market estimate about ₹8,400 crore across listed diagnostics names. As one of the only listed pure-play "arms dealers" to the sector, a fresh proxy like this can pull some of that flow over time.

The risk in one line

Slow organic growth, thin margins, and its biggest customers - the large labs - can always start doing this work themselves, which caps the opportunity.

My read

Not a listing-day lottery. A small, profitable, fairly-priced proxy on a structurally massive market - the kind of patient, long-term small-cap bet you size carefully and hold, not flip.

Sahi jagah, sahi size, thoda intezaar.

Educational only, not investment advice. SME IPOs are high-risk. DYOR.

The original thread: my post on X Follow along: @tyrovirtuoso on X